Webinars & Presentations

Learn how to drive your biologics development forward by leveraging MaxCyte’s flow electroporation technology. This flexible, scalable technology enables alternative strategies for the rapid development of high-yielding stable cell lines and can deliver gram-scale transient protein production within two weeks. Hosted with Labroots on September 12, 2023.

Hosted at Stanford University on July 6, 2023. Access this on demand seminar and learn more about how academic & industry labs utilize MaxCyte’s platforms to efficiently engineer primary cells, stem cells, and cell lines all while maintaining high cell viabilities & recovery for applications such as CRISPR, cell-based assays, protein production, viral production and more.

Non-viral site directed CAR integration can be accomplished using CRISPR/Cas9 and double-stranded DNA (dsDNA) via homology-directed repair (HDR), however yields with this approach have been limiting for clinical application. We discuss here a targeted but HDR-independent approach for the manufacture of CAR-T cell therapies – Presented during JSGE, June 2023

Global Challenges, Opportunities, and Views from the United States, Europe, and Asia – Presented during ASGCT 2023

Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The quality of CAR-T cell products, including T-cell memory signatures and exhaustion-related markers, is critical for the function of CAR-T cell therapies. We have developed novel piggyBac transposon (PB) -based CAR-T cells with favorable characteristics and durable antitumor efficacy against solid malignancies. Webinar broadcasted on Labroots March 30, 2023.

Abstract: Recent breakthroughs in autologous cellular therapies have generated tremendous excitement for the industry; however, these advances have been confronted with the expense of manufacturing of viral gene delivery and concerns over random integration and the safety of viral vectors. To combat these challenges, researchers at the University of California San Francisco have developed a novel system that offers lower toxicity with a single-stranded DNA (ssDNA) approach. This webinar was broadcasted on Labroots on May 24th, 2022.

A mammalian antibody display library was constructed using TALEN-mediated integration enabled by Maxcyte STx electroporation. Improved antibody variants exhibited optimal biophysical properties, including high solubility, low aggregation and low T cell immune response, all of which could help to avoid costly, late-stage, clinical failures of protein drugs. Webinar presented October 19, 2022

With our best-in-class delivery system, our team of scientific experts helps our collaborators unlock the potential of their products by solving development and commercialization challenges. This session will feature success stories from two of our client advocates, Dr. Jonathan Yen and Dr. Alicja Copik. Their talks will showcase MaxCyte’s focus on high-performance cellular editing and our outstanding technical support to enable our customers to use a single unifying technology, from concept to clinic. Presentation recorded during ASGCT Annual meeting May 16, 2022.

During this insightful webinar, Professor Denis Migliorini, a renowned expert in the field, will discuss the latest advancements in utilizing multivalent RNA CAR-T cells for the treatment of malignant glioma. The presentation will cover the development, potential benefits, and ongoing research in this groundbreaking area of cancer immunotherapy. Webinar broadcasted live through Labroots May 16, 2023.